ViiV

News

Group of young multiracial woman with red ribbons in hands are struggling against HIV/AIDS. AIDS awareness concept.

ViiV hopes for blockbuster with HIV drug combo approval

The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for treatment-naïve patients, making it the only company to have such a drug on

Views & Analysis

R&D round-up: Non-opioid painkiller space heats up

As the MHRA announced that it would be convening an Expert Working

News

Once-a-month HIV treatment sees promising phase III results

Janssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III trials.

News

ViiV redeems voucher for fast FDA review of HIV combination

ViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine.

News

GSK's blockbuster HIV drug linked with birth defects

Regulators issue warning after preliminary study findings

News

Stop obsessing about generic Advair, says GSK's Witty

Growth elsewhere will soak up impact of US competitor, says Sir Andrew Witty.

ViiV hopes for blockbuster with HIV drug combo approval

R&D round-up: Non-opioid painkiller space heats up

Once-a-month HIV treatment sees promising phase III results

ViiV redeems voucher for fast FDA review of HIV combination

GSK's blockbuster HIV drug linked with birth defects

Stop obsessing about generic Advair, says GSK's Witty

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

ViiV

Editor's Picks